Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation.

OBJECTIVE--To evaluate the prognostic significance of plasma N-terminal pro-atrial natriuretic factor (1-98) concentrations measured in the subacute phase after acute myocardial infarction, and to compare the predictive value of measurement of N-terminal pro-atrial natriuretic factor (1-98) with the measurement of atrial natriuretic factor (99-126) and with clinical assessment of the degree of heart failure. DESIGN--Prospective observational. SETTING--Norwegian central hospital. PATIENTS--139 patients (mean (SD) age 66.9 (11.1) years, 71.2% males) with acute myocardial infarction. Patients in cardiogenic shock or with severe heart failure (New York Heart Association class IV) were excluded. MAIN OUTCOME MEASURE--Cardiovascular death within 12 months. RESULTS--During the follow up period 15 patients died. In a univariate Cox proportional hazards model N-terminal pro-atrial natriuretic factor (1-98) was significantly related to mortality (p = 0.0003). In a multivariate model the prognostic value of N-terminal pro-atrial natriuretic factor (1-98) was better than that of atrial natriuretic factor (99-126) and clinical assessment of heart failure (N-terminal pro-atrial natriuretic factor (1-98), p = 0.0003; atrial natriuretic factor (99-126), p = 0.4513; heart failure, p = 0.0719). The odds ratio estimate of patients in whom plasma concentrations of N-terminal pro-atrial natriuretic factor (1-98) were greater than 2000 pmol/l was 25 (95% confidence interval 2.8-225.0) compared with patients with plasma concentrations less than 1000 pmol/l. CONCLUSIONS--These results suggest that determination of plasma N-terminal pro-atrial natriuretic factor (1-98) in the subacute phase of myocardial infarction may provide clinically relevant prognostic information that is superior to that obtained from atrial natriuretic factor (99-126) measurements and clinical evaluation.

[1]  R. Busse,et al.  Neurohormonal Inhibition and Hemodynamic Unloading During Prolonged Inhibition of ANF Degradation in Patients With Severe Chronic Heart Failure , 1992, Circulation.

[2]  K. Swedberg,et al.  Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) , 1992, The New England journal of medicine.

[3]  N. Arakawa,et al.  Plasma atrial natriuretic factor in patients with acute myocardial infarction. , 1992, Japanese heart journal.

[4]  T. Pindborg,et al.  Plasma concentration of atrial natriuretic peptide at admission and risk of cardiac death in patients with acute myocardial infarction , 1992, British heart journal.

[5]  R. Wyeth,et al.  Exercise increases the circulating concentration of the N-terminus of the atrial natriuretic factor prohormone in normal individuals. , 1991, American heart journal.

[6]  M. A. Plant.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality , 1991 .

[7]  O Odemuyiwa,et al.  Comparison of the predictive characteristics of heart rate variability index and left ventricular ejection fraction for all-cause mortality, arrhythmic events and sudden death after acute myocardial infarction. , 1991, The American journal of cardiology.

[8]  M. Murphy,et al.  Acute and sustained release of the atrial natriuretic factor prohormone N-terminus with acute myocardial infarction. , 1991, The American journal of the medical sciences.

[9]  K. Nakao,et al.  Expression and Distribution of Atrial Natriuretic Peptide in Human Hypertrophic Ventricle of Hypertensive Hearts and Hearts With Hypertrophic Cardiomyopathy , 1991, Circulation.

[10]  N. Markandu,et al.  N-terminal pro atrial natriuretic peptide in human plasma. , 1990, American journal of hypertension.

[11]  N. Arakawa,et al.  Renal, hormonal, and hemodynamic effects of low-dose infusion of atrial natriuretic factor in acute myocardial infarction. , 1990, American heart journal.

[12]  K. Dickstein,et al.  Plasma atrial natriuretic factor concentration during maximal cardiopulmonary exercise in men with mild heart failure. , 1990, International journal of cardiology.

[13]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[14]  T. Benraad,et al.  Storage and thawing influence plasma levels of immunoreactive atrial natriuretic peptide. , 1990, Clinica chimica acta; international journal of clinical chemistry.

[15]  N. Markandu,et al.  Concentrations of N-terminal ProANP in human plasma: evidence for ProANP (1-98) as the circulating form. , 1990, Clinica chimica acta; international journal of clinical chemistry.

[16]  D. Martin,et al.  Three peptides from the ANF prohormone NH(2)-terminus are natriuretic and/or kaliuretic. , 1990, The American journal of physiology.

[17]  K. Nakao,et al.  Appearance of atrial natriuretic peptide in the ventricles in patients with myocardial infarction. , 1990, American heart journal.

[18]  D. vesely,et al.  Prohormone atrial natriuretic peptides 1-98 and 31-67 increase with exercise in congestive heart failure patients. , 1989, The American journal of the medical sciences.

[19]  T. Benraad,et al.  Atrial natriuretic peptide after myocardial infarction. , 1989, American heart journal.

[20]  D. vesely,et al.  The N-terminus and a 4,000-MW peptide from the midportion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. , 1989, Circulation.

[21]  S. Gottlieb,et al.  Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. , 1989, Journal of the American College of Cardiology.

[22]  M. Kinoshita,et al.  Plasma atrial natriuretic polypeptide as an index of left ventricular end-diastolic pressure in patients with chronic left-sided heart failure. , 1989, American heart journal.

[23]  H. Tomoda.  Atrial natriuretic peptide in acute myocardial infarction. , 1988, The American journal of cardiology.

[24]  K. Nakao,et al.  γ-Atrial natriuretic polypeptide (γANP)-derived peptides in human plasma: Cosecretion of N-terminal γANP fragment and αANP , 1988 .

[25]  J. Sundsfjord,et al.  Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. , 1988, The Journal of clinical endocrinology and metabolism.

[26]  N. Seidah,et al.  NH2-terminal fragment of rat pro-atrial natriuretic factor in the circulation: Identification, radioimmunoassay and half-life , 1988, Peptides.

[27]  R. Zimmerman,et al.  Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. , 1988, Circulation research.

[28]  D. A. Baeyens,et al.  Atrial natriuretic prohormone peptides 1-30, 31-67, and 79-98 vasodilate the aorta. , 1987, Biochemical and biophysical research communications.

[29]  R M Whitlock,et al.  Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. , 1987, Circulation.

[30]  H. Matsubara,et al.  The role of atrial pressure in secreting atrial natriuretic polypeptides. , 1987, American heart journal.

[31]  N. Seidah,et al.  The propeptide Asn1-Tyr126 is the storage form of rat atrial natriuretic factor. , 1987, The Biochemical journal.

[32]  E. Espiner,et al.  HAEMODYNAMIC EFFECTS OF ATRIAL PEPTIDE INFUSION IN HEART FAILURE , 1986, The Lancet.

[33]  E. Bates,et al.  The relationship between plasma levels of immunoreactive atrial natriuretic hormone and hemodynamic function in man. , 1986, Circulation.

[34]  R. Cuneo,et al.  Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. , 1986, Life sciences.

[35]  M. Webster,et al.  RENAL, HAEMODYNAMIC, AND HORMONAL EFFECTS OF HUMAN ALPHA ATRIAL NATRIURETIC PEPTIDE IN HEALTHY VOLUNTEERS , 1985, The Lancet.